文献速递垂体与肾上腺疾病

糖皮质激素诱导的肾上腺功能不全患者的诊疗方法

Approach to the Patient With Glucocorticoid-induced Adrenal Insufficiency.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

糖皮质激素诱导的肾上腺功能不全是外源性糖皮质激素抑制下丘脑-垂体-肾上腺轴所致,为最常见的肾上腺功能不全类型,有危及生命的肾上腺危象风险。诊断依靠ACTH兴奋试验等刺激试验;口服糖皮质激素治疗期间或停药初期约50%患者存在肾上腺功能不全,但临床研究中仅≤1%患者有肾上腺功能检测记录。超过70%病例在急性入院时被发现,症状非特异易漏诊;严重者治疗遵循中枢性肾上腺功能不全原则,轻度-中度及应激剂量指征尚不明确。

要点

  • 口服糖皮质激素治疗期间或停药初期约50%患者存在肾上腺功能不全,但临床实践中≤1%患者有肾上腺功能检测记录。
  • 超过70%病例在急性入院时被识别,症状非特异且与基础病重叠,容易漏诊。
  • 严重糖皮质激素诱导的肾上腺功能不全治疗遵循中枢性肾上腺功能不全原则;轻度-中度治疗后是否治疗及应激剂量指征尚未确立。

核心结论

  • 糖皮质激素诱导的肾上腺功能不全是外源性糖皮质激素抑制下丘脑-垂体-肾上腺轴所致,为最常见的肾上腺功能不全类型,因肾上腺危象风险和生活质量影响而重要。
  • 诊断依靠ACTH兴奋试验等刺激试验;口服糖皮质激素治疗期间或停药初期约50%患者存在肾上腺功能不全,但临床研究中仅≤1%患者有肾上腺功能检测记录。
  • 超过70%病例在急性入院时被发现;严重者治疗遵循中枢性肾上腺功能不全原则,轻度-中度者治疗指征及应激剂量指征尚未确立。

研究设计与样本

  • 本文为综述,回顾糖皮质激素诱导的肾上腺功能不全的多个方面并讨论常见临床情况下的诊疗方法。

主要发现

  • 口服糖皮质激素治疗期间或停药初期约50%患者存在肾上腺功能不全,但临床研究中仅≤1%患者有肾上腺功能检测记录。
  • 超过70%病例在急性入院时被识别,症状非特异且与基础病及并发情况重叠,诊断容易遗漏。
  • 已确诊糖皮质激素诱导的肾上腺功能不全患者中,自我管理信心不足及急性肾上腺危象时糖皮质激素给药延迟比例高。

关键数值与推荐

  • 诊断采用ACTH兴奋试验等刺激试验。
  • 严重糖皮质激素诱导的肾上腺功能不全治疗遵循中枢性肾上腺功能不全原则。
  • 轻度-中度肾上腺功能不全在糖皮质激素停药后是否治疗及治疗指征尚未确立。
  • 糖皮质激素治疗期间追加应激剂量糖皮质激素的指征尚不明确。

临床怎么用

  • 对口服糖皮质激素治疗期间或停药初期患者,应依据ACTH兴奋试验等刺激试验诊断糖皮质激素诱导的肾上腺功能不全。
  • 严重糖皮质激素诱导的肾上腺功能不全按中枢性肾上腺功能不全原则治疗。
  • 需提高临床医生和患者对糖皮质激素诱导的肾上腺功能不全的认识与教育,以改善自我管理和急性肾上腺危象时的糖皮质激素给药延迟。

局限性

  • 糖皮质激素停药后轻度-中度肾上腺功能不全的临床意义及治疗指征尚未确立。
  • 糖皮质激素治疗期间追加应激剂量糖皮质激素的指征尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Glucocorticoid-induced adrenal insufficiency is caused by exogenous glucocorticoid suppression of the hypothalamic-pituitary-adrenal axis and is the most prevalent form of adrenal insufficiency. The condition is important to diagnose given the risk of life-threatening adrenal crisis and impact on patients' quality of life. The diagnosis is made with a stimulation test such as the ACTH test. Until now, testing for glucocorticoid-induced adrenal insufficiency has often been based on clinical suspicion rather than routinely but accumulating evidence indicates that a significant number of cases will remain unrecognized. During ongoing oral glucocorticoid treatment or initially after withdrawal, ~50% of patients have adrenal insufficiency, but, outside clinical studies, ≤ 1% of patients have adrenal testing recorded. More than 70% of cases are identified during acute hospital admission, where the diagnosis can easily be missed because symptoms of adrenal insufficiency are nonspecific and overlap those of the underlying and intercurrent conditions. Treatment of severe glucocorticoid-induced adrenal insufficiency should follow the principles for treatment of central adrenal insufficiency. The clinical implications and thus indication to treat mild-moderate adrenal deficiency after glucocorticoid withdrawal has not been established. Also, the indication of adding stress dosages of glucocorticoid during ongoing glucocorticoid treatment remains unclear. In patients with established glucocorticoid-induced adrenal insufficiency, high rates of poor confidence in self-management and delayed glucocorticoid administration in the acute setting with an imminent adrenal crisis call for improved awareness and education of clinicians and patients. This article reviews different facets of glucocorticoid-induced adrenal insufficiency and discusses approaches to the condition in common clinical situations.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Borresen SW, Klose M, Glintborg D, et al. Approach to the Patient With Glucocorticoid-induced Adrenal Insufficiency. J Clin Endocrinol Metab. 2022. PMID: 35302603. doi:10.1210/clinem/dgac151

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。